6 results
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... #Cancer #Algorithm ... #Anticoagulation ... #Management #Hematology ... #Oncology
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
for VTE in Malignancy ... #Cancer #Algorithm ... #Anticoagulation ... #Management #Hematology ... #Oncology
Causes of Breakthrough/Extension of Thrombosis and Management Algorithm

#Anticoagulation #Breakthrough #Thrombosis #Algorithm #Extension #VTE #DVT #Hematology #Management
Causes of Breakthrough ... Thrombosis and Management ... Algorithm #Anticoagulation ... #Extension #VTE ... #DVT #Hematology
Clotmaster Consensus 2019: Duration of Therapy for Venous Thromboembolic Disease
 • Superficial Venous Thrombosis
 • Upper
Thrombophilia • Cancer ... DeLoughery @Bloodman #VTE ... #anticoagulation ... #duration #management ... #DVT #hematology
Longterm Venous Thromboembolism Treatment Algorithm
Treat for 3 months and reassess
 • Isolated distal DVT (without cancer)
Thromboembolism Treatment Algorithm ... therapy - Second VTE ... Thromboembolism #Treatment #Algorithm ... #management #hematology ... #anticoagulation
Essential Thrombocythemia (ET)
ET is a chronic myeloproliferative neoplasm. Most cases are related to mutations that affect
• Treatment algorithms ... Hydroxyurea + anticoagulation ... Thrombocythemia #ET #hematology ... #diagnosis #management ... #hematology